Generate Biomedicines Inc. (GENB)
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GENB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.23B
- EPS (TTM)
- -$2.49
- Dividend yield
- None
- 52-week range
- 9.40 – 22.67
- Day range
- 9.40 – 10.58
- Volume / Avg
- 967.20K / 1.24M
- Beta
- —
- Shares outstanding
- 129.10M
52-week range
GENB stock today
On Nov 20, GENB ended the session at $9.54, shedding $0.83 (8.00%), versus the S&P 500's 3.70% decline. At this level, GENB sits near the bottom of its 52-week range of $9.40 to $22.67: 57.9% below the high, set on Aug 25, 2026 and 1.5% above the low. Generate Biomedicines has posted a net loss over the last twelve months (EPS of -$2.49), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Generate Biomedicines
Company profileGenerate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael T. Nally M.B.A.
- Headquarters
- Somerville, MA
- Employees
- 312
- IPO year
- 2026
- Website
- generatebiomedicines.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$27.00+183.02%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.68 vs $-0.50
- Surprise
- -36.00%
GENB news
All GENB news- Generate Biomedicines, Inc. reports Q3 resultsSeeking Alpha
- Generate Biomedicines Reports Q3 Results; Cash Runway Extends Into First Half Of 2028; Stock DownNasdaqGENB, LEN.B
- Generate Biomedicines, Inc Q3 Sales DeclineNasdaqGENB, BF.A
- Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Nvidia Plays Kingmaker Again. Why the Meta Deal Is a Winning Move.NasdaqNVDA, META, NOK, INTC
- Generate Biomedicines to Participate in November Investor ConferencesGlobeNewswire
- Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic DiseasesNasdaqET, GENB
- Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGlobeNewswire
Generate Biomedicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs GENB |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs GENB |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs GENB |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs GENB |
| LBRXLB Pharmaceuticals Inc | 38.85 | -2.97% | $1.26B | vs GENB |
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs GENB |
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs GENB |
| AVLNAvalyn Pharma Inc. | 28.40 | -1.05% | $1.26B | vs GENB |
Indexes, lists and sector
Generate Biomedicines stock FAQ
What is Generate Biomedicines's stock price today?
GENB last traded at $9.54 as of Nov 20, 4:00 PM EST, down 8.00% on the day. Prices are delayed at least 15 minutes.
Who is Generate Biomedicines's CEO?
Mr. Michael T. Nally M.B.A. is the chief executive officer of Generate Biomedicines Inc., which has about 312 employees.
What is the GENB 52-week high?
The 52-week high for GENB is $22.67 and the 52-week low is $9.40. The stock is currently 57.9% below its high.